Abstract:The recent Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola and Zika virus outbreaks exemplify the continued threat of (re-)emerging viruses to human health, and our inability to rapidly develop effective therapeutic countermeasures. Many viruses, including MERS-CoV and the Crimean-Congo hemorrhagic fever virus (CCHFV) encode deubiquitinating (DUB) enzymes that are critical for viral replication and pathogenicity. They bind and remove ubiquitin (Ub) and interferon stimulated gene 15 (ISG15) from cellular proteins to suppress host antiviral innate immune responses. A variety of viral DUBs (vDUBs), including the MERS-CoV papain-like protease, are responsible for cleaving the viral replicase polyproteins during replication, and are thereby critical components of the viral replication cycle. Together, this makes vDUBs highly attractive antiviral drug targets. However, structural similarity between the catalytic cores of vDUBs and human DUBs complicates the development of selective small molecule vDUB inhibitors. We have thus developed an alternative strategy to target the vDUB activity through a rational protein design approach. Here, we report the use of phage-displayed ubiquitin variant (UbV) libraries to rapidly identify potent and highly selective protein-based inhibitors targeting the DUB domains of MERS-CoV and CCHFV. UbVs bound the vDUBs with high affinity and specificity to inhibit deubiquitination, deISGylation and in the case of MERS-CoV also viral replicative polyprotein processing. Co-crystallization studies further revealed critical molecular interactions between UbVs and MERS-CoV or CCHFV vDUBs, accounting for the observed binding specificity and high affinity. Finally, expression of UbVs during MERS-CoV infection reduced infectious progeny titers by more than four orders of magnitude, demonstrating the remarkable potency of UbVs as antiviral agents. Our results thereby establish a strategy to produce protein-based inhibitors that could protect against a diverse range of viruses by providing UbVs via mRNA or protein delivery technologies or through transgenic techniques.

Chemistry-based functional proteomics to identify novel deubiquitylating enzymes involved in viral infection.

The Role of Deubiquitinases in Virus Replication and Host Innate Immune Response

The Functional Deubiquitinating Enzymes in Control of Innate Antiviral Immunity

An Integrated View of Deubiquitinating Enzymes Involved in Type I Interferon Signaling, Host Defense and Antiviral Activities

Role of Virally-Encoded Deubiquitinating Enzymes in Regulation of the Virus Life Cycle

Viral deubiquitinating proteases and the promising strategies of their inhibition

Detecting Active Deconjugating Enzymes with Genetically Encoded Activity-Based Ubiquitin and Ubiquitin-like Protein Probes

Cellular Deubiquitylating Enzyme: A Regulatory Factor of Antiviral Innate Immunity

Potent and Selective Inhibition of Pathogenic Viruses by Engineered Ubiquitin Variants

On the Study of Deubiquitinases: Using the Right Tools for the Job

Viral deubiquitinases and innate antiviral immune response in livestock and poultry

Protein Engineering in the Ubiquitin System: Tools for Discovery and Beyond

Functional analysis of deubiquitylating enzymes in tumorigenesis and development

Recent Progress of Deubiquitinating Enzymes in Human and Plant Pathogenic Fungi

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes

Epstein-barr virus encodes three bona fide ubiquitin-specific proteases

Viral Proteomics: the Emerging Cutting-Edge of Virus Research

The Role of Deubiquitinases in Oncovirus and Host Interactions

Activity-Based Ubiquitin Probes for Investigation of Deubiquitinases

Generating Intracellular Modulators of E3 Ligases and Deubiquitinases from Phage-Displayed Ubiquitin Variant Libraries.